---
document_datetime: 2025-12-08 09:57:51
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/filspari-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: filspari-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.055406
conversion_datetime: 2025-12-20 15:18:07.268711
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## FILSPARI

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 13/11/2025                          |                                             | SmPC                             | The applicant submitted this variation to update |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000287206                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.1 of the SmPC in order to add a modified intention-to-treat analysis from all subjects in the study PROTECT (021IGAN17001); this is the global, phase 3, multicenter, randomized, double-blind, parallel-group, active controlled study designed to evaluate the efficacy and safety of sparsentan (target dose 400 mg once daily [QD]) versus irbesartan (target dose 300 mg QD) in patients with IgAN.   |            |      | section 5.1 of the SmPC by adding a modified intention-to-treat analysis from all subjects in the Phase 3 PROTECT double-blind study. They provided study 021IGAN17001 (PROTECT), ADDENDUM 1, to support the proposed changes to the SmPC. The PROTECT is a global, Phase 3, multicenter, randomised, double-blind, parallel-group, active controlled study designed to evaluate the efficacy and safety of sparsentan (target dose 400 mg once daily) vs irbesartan (target dose 300 mg QD) in patients with IgAN. The updated results from PROTECT continue to demonstrate the efficacy of sparsentan in reducing proteinuria and preserving kidney function, with a similar safety profile, compared to irbesartan. The applicant provided an exceptional rationale justifying the proposed update's relevance, robustness, and necessity for prescribers, which was agreed by the CHMP. For more information, please refer to the Summary of   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000280770 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted C.I HUMAN AND VETERINARY MEDICINAL                                                                                                                                                                                                                                                                                                       | 13/11/2025 | SmPC | This grouped application led to an update of section 4.5 of the SmPC with the addition of drug-drug interaction information stemming from three drug- drug-interaction studies, which were requested by the CHMP at the time of Filspari approval. They concern the in vivo induction potential of sparsentan towards CYP2C9 and inhibition potential towards CYP3A as well as the effect of pregnane X receptor inducer on sparsentan. For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                       | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Grouped application to update section 4.5 of the SmPC to add the drug-drug interaction information from three drug-drug-interaction studies regarding the in vivo induction potential of sparsentan towards CYP2C9 and inhibition potential towards CYP3A as well as the effect of pregnane X receptor inducer on   |            |     |             |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| PSUR / EMA/PSUR/0000274455            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 02/10/2025 |     | Maintenance |
| Variation type IA / EMA/VR/0000301836 | B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 29/09/2025 | N/A |             |

<div style=\"page-break-after: always\"></div>

| Variation type IA_IN / EMA/VR/0000294087   | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer - Accepted   | 04/09/2025   | N/A   |
|--------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type IB / EMA/VR/0000284661      | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted                                                                                             | 04/08/2025   | N/A   |
| Variation type IA / EMA/VR/0000256648      | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                        | 11/03/2025   | N/A   |